{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:46:50Z","timestamp":1791704810366,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.tranon.2026.103017","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T12:14:47Z","timestamp":1788696887000},"page":"103017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patient-derived organoids as predictor of clinical response in ovarian cancer: a systematic review"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9793-0104","authenticated-orcid":false,"given":"Merel","family":"Vegter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0338-7824","authenticated-orcid":false,"given":"Prakriti","family":"Garkhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gatske M.","family":"Nieuwenhuyzen-de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-6346","authenticated-orcid":false,"given":"Ingrid A.","family":"Boere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen J.","family":"van Beekhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tranon.2026.103017_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.tranon.2026.103017_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."},{"issue":"10177","key":"10.1016\/j.tranon.2026.103017_bib0003","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"10538","key":"10.1016\/j.tranon.2026.103017_bib0004","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","article-title":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study","volume":"407","author":"Colombo","year":"2026","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.tranon.2026.103017_bib0005","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u0391-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.tranon.2026.103017_bib0006","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.tranon.2026.103017_bib0007","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13046-022-02486-z","article-title":"Harnessing preclinical models for the interrogation of ovarian cancer","volume":"41","author":"Qin","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.tranon.2026.103017_bib0008","doi-asserted-by":"crossref","first-page":"19714","DOI":"10.1002\/cam4.6521","article-title":"Patient-derived organoid culture in epithelial ovarian cancers\u2014techniques, applications, and future perspectives","volume":"12","author":"Chan","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.tranon.2026.103017_bib0009","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/organoids4040023","article-title":"Organoids as next-generation models for tumor heterogeneity, personalized therapy, and cancer research: advancements, applications, and future directions","volume":"4","author":"Madan","year":"2025","journal-title":"Organoids"},{"issue":"1","key":"10.1016\/j.tranon.2026.103017_bib0010","article-title":"In vitro drug testing using patient-derived ovarian cancer organoids","volume":"17","author":"Chen","year":"2024","journal-title":"J. Ovarian Res."},{"issue":"11","key":"10.1016\/j.tranon.2026.103017_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107762","article-title":"Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses","volume":"31","author":"de Witte","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.tranon.2026.103017_bib0012","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/biomedicines9081021","article-title":"Utilizing patient-derived epithelial ovarian cancer tumor organoids to predict carboplatin resistance","volume":"9","author":"Gorski","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.tranon.2026.103017_bib0013","doi-asserted-by":"crossref","unstructured":"Gray H.J, Chatterjee P., Rosati R., Appleyard L.R, Durenberger G.J, Diaz R.L, et al. Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing. NPJ Precis. Oncol. 2023 7:1. 2023;7(1):45-. doi:10.1038\/s41698-023-00379-8.","DOI":"10.1038\/s41698-023-00379-8"},{"key":"10.1016\/j.tranon.2026.103017_bib0014","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.tranon.2026.103017_bib0015","first-page":"33","article-title":"Ovarian cancer patient-derived organoids used as a model for replicating genetic characteristics and testing drug responsiveness: a preliminary study","author":"Chang","year":"2024","journal-title":"Cell Transplant."},{"issue":"2","key":"10.1016\/j.tranon.2026.103017_bib0016","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s13577-022-00827-w","article-title":"Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs","volume":"36","author":"Ito","year":"2023","journal-title":"Hum. Cell"},{"issue":"1","key":"10.1016\/j.tranon.2026.103017_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47578-7","article-title":"Prospective validation of an ex vivo, patient-derived 3D spheroid model for response predictions in newly diagnosed ovarian cancer","volume":"9","author":"Shuford","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.tranon.2026.103017_bib0018","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12967-025-07112-y","article-title":"Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer","volume":"24","author":"Wang","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tranon.2026.103017_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106232","article-title":"Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer","volume":"179","author":"Tao","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tranon.2026.103017_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122087","article-title":"High-throughput organo-on-pillar (high-TOP) array system for three-dimensional ex vivo drug testing","volume":"296","author":"Jun","year":"2023","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.tranon.2026.103017_bib0021","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.devcel.2023.04.012","article-title":"A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids","volume":"58","author":"Senkowski","year":"2023","journal-title":"Dev. Cell"},{"issue":"1","key":"10.1016\/j.tranon.2026.103017_bib0022","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1186\/s12885-025-14811-8","article-title":"Organoid models established from primary tumors and patient-derived xenograft tumors reflect platinum sensitivity of ovarian cancer patients","volume":"25","author":"Nikeghbal","year":"2025","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.103017_bib0023","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s13046-025-03537-x","article-title":"Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response","volume":"44","author":"Thorel","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.tranon.2026.103017_bib0024","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2026.103017_bib0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating recist 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"8","key":"10.1016\/j.tranon.2026.103017_bib0026","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1097\/IGC.0000000000001061","article-title":"The use of endometrial cancer patient\u2013derived organoid culture for drug sensitivity testing is feasible","volume":"27","author":"Girda","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.103017_bib0027","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12885-025-13590-6","article-title":"The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors","volume":"25","author":"Le","year":"2025","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.tranon.2026.103017_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108198","article-title":"Patient-derived organoids as personalized avatars and a potential immunotherapy model in cervical cancer","volume":"26","author":"Huang","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.tranon.2026.103017_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"23","key":"10.1016\/j.tranon.2026.103017_bib0030","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-25-1564","article-title":"Patient-derived organoids predict treatment response in metastatic colorectal cancer","volume":"31","author":"Smabers","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.tranon.2026.103017_bib0031","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7150\/thno.96027","article-title":"Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development","volume":"14","author":"Xiang","year":"2024","journal-title":"Theranostics"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:30:08Z","timestamp":1791703808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326003530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"alternative-id":["S1936523326003530"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103017","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-derived organoids as predictor of clinical response in ovarian cancer: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103017"}}